Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
BörsenkürzelGCTK
Name des UnternehmensGlucoTrack Inc
IPO-datumApr 09, 2013
CEOGoode (Paul V)
Anzahl der mitarbeiter11
WertpapierartOrdinary Share
GeschäftsjahresendeApr 09
Addresse301 Rt 17 North
StadtRUTHERFORD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl07070
Telefon197286757878
Websitehttps://glucotrack.com/
BörsenkürzelGCTK
IPO-datumApr 09, 2013
CEOGoode (Paul V)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten